Sign in
Taking people in United StatesNo phase

Watching brain metastases closely instead of treating them right away during drug therapy

Studies safety of close monitoring for brain metastases in people on brain-reaching drug treatment.

Key facts

Who runs it
University of California, Irvine
Where
Orange, United StatesSee the site
Trial code
Registry title
PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
Status
Recruiting
People taking part
12 people, planned
Started
4 Aug 2026
Expected to end
Aug 2028
Type of study
Observational
Record updated
18 September 2026

Who can take part

The trial is looking for adults with cancer that has spread to the brain, without symptoms from it. They must be about to start a new drug treatment that may work in the brain. Radiation or surgery to the brain is held back while doctors watch closely.

Age
18 years and older
Sex
All sexes
Disease stage
Metastatic cancer that is not a blood cancer, confirmed by tissue or cell tests. At least one new or growing brain metastasis that has not been treated with surgery or radiation. No active brain metastasis larger than 3cm (1.2 in). Spread to the lining of the brain (leptomeningeal disease) is allowed. KPS performance status ≥50%. Life expectancy of ≥3 months.
Earlier treatment
The brain metastasis must not have had surgery or radiation before. People must not have had the planned new drug treatment before. Other drugs of a similar class may be allowed if the treating team agrees.
Main reasons for not taking part
  • Only growth of brain lesions that were already treated with surgery or radiation
  • Symptoms from active brain metastases
  • Needing steroids, seizure drugs or other comfort medicines for brain metastases
  • Conditions that prevent having an MRI scan
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Patients must have histologically or cytologically confirmed metastatic non-hematologic malignancy
  • Patients must have at least one new or progressive brain metastasis that has not received prior local therapy (surgery or radiation therapy)
  • Patients must have no active brain metastasis >3cm in size
  • Leptomeningeal disease is permitted
  • Patients with only non-measurable disease as defined by the RANO-BM criteria are permitted so long as the clinical determination of new or progressive disease has been made by the treating team
  • Patients must have no symptoms attributable to active brain metastases
  • At the time of enrollment, patients must be eligible for AND planning to begin a new line of systemic therapy with potential for CNS-efficacy. Determination of potential for CNS-efficacy will be determined based on the clinical judgement of the treating physicians. Patients must have had no prior exposure to the specific systemic therapy in question at the time of enrollment, though exposure to other medications from a similar class are acceptable at the discretion of the treating team
  • Patient must be planning to defer radiation therapy to trial medical therapy regardless of enrollment on trial
  • Must be age ≥ 18 years
  • Patients must be willing to complete MoCA and FACT-BR assessments (refer to section 4.4.1)
  • Performance status: KPS performance status ≥50%
  • Life expectancy of ≥3 months
  • Ability to understand and willingness to sign a written informed consent document

Who cannot take part

  • Patients who have only progressive growth of brain lesions that have previously been treated with surgery or radiation therapy
  • Patients requiring corticosteroids, anticonvulsants, or other palliative medications related to brain metastases
  • Patients with conditions that exclude them from undergoing magnetic resonance imaging
  • Patients with active symptomatic brain metastases

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Brain cancer or nervous system cancer or CNS cancer

This trial is currently available in United States.

  • Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Aaron Simon, MDTaking people

About the trial

What the trial wants to find out

This is a Pilot clinical trial determining the safety of an active surveillance approach to local therapy in subjects with brain metastases. These are subjects who are undergoing CNS-penetrating systemic therapy.

The group in the trial

  • SingleArm

    CNS-Penetrating Systemic Therapy

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study Assessing the Safety of an Active Surveillance Approach to Local Therapy in Patients With Brain Metastases Undergoing CNS-Penetrating Systemic Therapy
Plain-language title
Watching brain metastases closely instead of treating them right away during drug therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07827001, who can take part
Record updated
18 September 2026